BenevolentAl Therapeutics Pipeline and Triage
Target R identified as a therapeutic target for GBM
Target R was predicted by the Benevolent Platform TM as a potential therapeutic target to:
Modulate viability of glioblastoma stem cells (GSC)
Sensitise with radiotherapy (Radiosensitiser)
Data from the "stem cell enriched" neurosphere assay
indicated that Target R had 'on-target', single agent activity
across majority of GBM patient cells but was less sensitive to
MES GPCs
Data from the 3D clonogenic assay indicated that
Target R had both 'on-target', single agent activity and
sensitised with ionising radiation
Target R
% Viability
PN-11
PN-20
MES-10
-
60-
40-
MES-25
PN-31
CL-12
20-
MES-42
MES-40
-4
-3
-2
-1
0
Log[2933] μM
-PN-45
Surviving fraction
1.2
0 Gy
3 Gy
1.0
0.8
0.6
0.4
Target R
IC50-
0.2
OGY 0.246 (0.201 to 0.291)
0.0
3Gy 0.104 (0.082 to 0.125)
p=0.00434
0.01
0.1
10
Concentration (μM)
ΑΙ
Benevolent 54View entire presentation